June 24 Company Quick Takes: Terns gains Chinese rights to elafibranor; plus venetoclax, Zejula and more

Terns gets Chinese rights to Genfit's liver disease candidate
Terns Pharmaceuticals Inc. (San Mateo, Calif.) licensed rights to elafibranor (GFT505) from Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) to treat non-alcoholic steatohepatitis and primary

Read the full 303 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE